Patrick Joseph Roberts

US Patent:

20110224227, Sep 15, 2011

Filed:

Oct 1, 2009

Appl. No.:

13/122061

Inventors:

Norman E. Sharpless - Chapel Hill NC, US
Jay C. Strum - Hillsborough NC, US
John E. Bisi - Apex NC, US
Patrick J. Roberts - Durham NC, US
Matthew R. Ramsey - Chapel Hill NC, US

International Classification:

A61K 31/497
A61K 31/519
A61K 31/505
A61K 31/4709
G01N 33/53
A61P 39/00

US Classification:

51425304, 5142581, 514256, 514314, 435 29

Abstract:

Methods for reducing or preventing the effects of cytotoxic compounds in healthy cells are provided. The methods relate to the use of selective cyclin-dependent kinase (CDK) 4/6 inhibitors to induce transient quiescence in CDK4/6 dependent cells, such as hematopoietic stem cells and/or hematopoietic progenitor cells. Also described is a method of selecting compounds for reducing or preventing the effects of cytotoxic agents compounds in healthy cells.

US Patent:

20120100100, Apr 26, 2012

Filed:

May 13, 2010

Appl. No.:

13/319828

Inventors:

Norman E. Sharpless - Chapel Hill NC, US
Patrick J. Roberts - Durham NC, US
Kwok Wong - Chapell Hill NC, US
Yan Liu - Austin TX, US
Soren Johnson - Chapel Hill NC, US

International Classification:

A61K 38/20
A61P 37/06
A61K 31/4155
A61K 31/497
A61K 38/19
A61K 38/18

US Classification:

424 852, 424 851, 514 78, 514 77, 514 76, 514 92, 514407, 51425211

Abstract:

The presently disclosed subject matter relates to methods and compositions for protecting healthy cells from damage due to DNA damaging agents. In particular, the presently disclosed subject matter relates to the protective action of selective cyclin dependent kinase 4/6 (CDK4/6) inhibitors administered to subjects that have been exposed to or that are at risk of exposure to DNA damage.

US Patent:

20130303543, Nov 14, 2013

Filed:

Nov 17, 2011

Appl. No.:

13/988158

Inventors:

Derek Paul DiRocco - Brookline MA, US
Norman Edward Sharpless - Chapel Hill NC, US
Jay Copeland Strum - Hillsborough NC, US
John Emerson Bisi - Apex NC, US
Patrick Joseph Roberts - Durham NC, US
Benjamin Duane Humphreys - Brookline MA, US
Kwok-Kin Wong - Arlington MA, US

Assignee:

The University of North Carolina at Chapel Hill - Chapel Hill NC

International Classification:

A61K 31/519

US Classification:

51425216

Abstract:

The presently disclosed subject matter relates to methods and compositions for protecting cells and or tissues from damage due to ischemia. In particular, the presently disclosed subject matter relates to the protective action of cyclin dependent kinase 4/6 (CDK4/6) lithibitors administered to subjects that have been exposed to, or that are at risk of, ischemia.

US Patent:

20220175780, Jun 9, 2022

Filed:

Aug 16, 2021

Appl. No.:

17/403577

Inventors:

- Research Triangle Park NC, US
John E. Bisi - Apex NC, US
Patrick Joseph Roberts - Durham NC, US
Jessica A. Sorrentino - Durham NC, US

International Classification:

A61K 31/519
A61K 31/4745
A61K 31/5375
A61K 31/5377
A61K 31/695

Abstract:

This invention is in the area of improved therapeutic combinations for and methods of treating selected retinoblastoma (Rb)-negative cancers and Rb-negative abnormal cellular proliferative disorders using particular topoisomerase inhibitors and specific cyclin-dependent kinase 4/6 (CDK4/6) inhibitors. In one aspect, the improved treatment of select Rb-negative cancers is disclosed using specific compounds disclosed herein in combination with a topoisomerase I inhibitor.

US Patent:

20210299130, Sep 30, 2021

Filed:

Apr 5, 2021

Appl. No.:

17/222873

Inventors:

- Research Triangle Park NC, US
John Emerson Bisi - Chapel Hill NC, US
Patrick Joseph Roberts - Durham NC, US
Francis Xavier Tavares - Durham NC, US

Assignee:

G1 Therapeutics, Inc. - Research Triangle Park NC

International Classification:

A61K 31/527
C07D 487/14
A61K 45/06
A61K 31/519
A61K 31/5377
A61P 35/04
A61P 35/00
A61K 9/00
A61K 31/555
A61K 31/7048

Abstract:

This invention is in the area of improved compounds, compositions and methods of transiently protecting healthy cells, and in particular hematopoietic stem and progenitor cells (HSPC) as well as renal cells, from damage associated with DNA damaging chemotherapeutic agents. In one aspect, improved protection of healthy cells is disclosed using disclosed compounds that act as highly selective and short, transiently-acting cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors when administered to subjects undergoing DNA damaging chemotherapeutic regimens for the treatment of proliferative disorders.

US Patent:

20210267986, Sep 2, 2021

Filed:

May 7, 2021

Appl. No.:

17/315011

Inventors:

- Research Triangle Park NC, US
Patrick Joseph Roberts - Durham NC, US
Jay Copeland Strum - Hillsborough NC, US

Assignee:

G1 Therapeutics, Inc. - Research Triangle Park NC

International Classification:

A61K 31/527
A61K 31/357
A61K 45/06
A61P 35/04

Abstract:

The present invention provides methods and compositions for treating cancers with a combination of eribulin and a selective CDK4/6 inhibitor, wherein the selective CDK4/6 inhibitor reduces eribulin's effects on myelosuppression and/or myeloablation without reducing the efficacy of eribulin therapy.

US Patent:

20210213022, Jul 15, 2021

Filed:

Feb 22, 2021

Appl. No.:

17/181638

Inventors:

- Research Triangle Park NC, US
John Emerson Bisi - Chapel Hill NC, US
Patrick Joseph Roberts - Durham NC, US
Francis X. Tavares - Durham NC, US

Assignee:

G1 Therapeutics, Inc. - Research Triangle Park NC

International Classification:

A61K 31/527
C07D 487/14
A61K 45/06
A61K 31/519
A61K 31/5377
A61P 35/04
A61P 35/00
A61K 9/00
A61K 31/555
A61K 31/7048

Abstract:

This invention is in the area of improved compounds for and methods of treating selected RB-positive cancers and other Rb-positive abnormal cellular proliferative disorders while minimizing the deleterious effects on healthy cells, for example healthy Hematopoietic Stem Cells and Progenitor Cells (HSPCs), associated with current treatment modalities. In one aspect, improved treatment of select RB-positive cancers is disclosed using specific compounds disclosed herein. In certain embodiments, the compounds described herein act as highly selective and, in certain embodiments, short, transiently-acting cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors when administered to subjects.

US Patent:

20210077498, Mar 18, 2021

Filed:

Nov 23, 2020

Appl. No.:

17/102311

Inventors:

- Research Triangle Park NC, US
John Emerson Bisi - Apex NC, US
Patrick Joseph Roberts - Durham NC, US
Francis Xavier Tavares - Durham NC, US

Assignee:

G1 Therapeutics, Inc. - Research Triangle Park NC

International Classification:

A61K 31/527
A61K 45/06
C07D 487/20
A61K 38/18
A61K 38/19
A61K 38/20
A61K 31/202
A61K 31/702
A61K 31/519
A61N 5/10

Abstract:

This invention is in the area of improved compounds and methods for transiently protecting healthy cells, and in particular hematopoietic stem and progenitor cells (HSPC), from the damage associated with ionizing radiation (IR) exposure using selective radioprotectants.